|
Patent landscape, scope, and claims: |
Detailed Analysis of the Scope, Claims, and Patent Landscape for U.S. Patent 6,251,368
Summary
U.S. Patent 6,251,368, granted on June 26, 2001, to AstraZeneca AB, broadly covers a method for treating inflammatory and autoimmune disorders using selective phosphodiesterase 4 (PDE4) inhibitors, specifically compounds such as roflumilast. This patent has played a pivotal role in establishing AstraZeneca's market position for PDE4 inhibitors used to treat respiratory and inflammatory conditions, notably chronic obstructive pulmonary disease (COPD) and psoriasis. Its extensive claims and strategic patent coverage have significantly influenced the development landscape for PDE4-targeted drugs. This analysis examines the patent’s scope, claims, and the broader patent landscape within the PDE4 inhibitor domain, providing insights for stakeholders involved in drug development, licensing, or patent litigation.
What is the Scope of U.S. Patent 6,251,368?
Background Context
The patent addresses novel chemical compounds—primarily roflumilast and related derivatives—that selectively inhibit PDE4 enzymes, thereby modulating inflammatory responses. PDE4 inhibitors increase intracellular cyclic AMP (cAMP) levels, suppressing cytokine release, leading to anti-inflammatory effects.
Chemical Scope
- Core compounds: The claims encompass compounds with the general formula (I), substituting various groups to generate a broad class of PDE4 inhibitors.
- Substituent variations: Specific heterocyclic, aromatic, and alkyl groups define different compounds within the scope.
- Preferred compounds: Roflumilast is explicitly exemplified as a preferred compound, but the patent claims extend to a wide array of derivatives.
Therapeutic Scope
- Diseases targeted: The patent specifically states treatment of respiratory diseases (e.g., COPD, asthma), autoimmune and inflammatory diseases (e.g., psoriasis, rheumatoid arthritis), and other inflammatory disorders.
- Method claims: Includes methods for treating these conditions by administering compounds falling within the defined chemical scope.
Legal Scope
- Claims coverage: The patent includes composition of matter claims for the compounds, method claims for their use, and sometimes process claims for their synthesis.
- Claim breadth: The claims are designed to cover not only known compounds like roflumilast but also novel derivatives that meet structural criteria.
Analysis of the Claims
| Type of Claim |
Scope/Content |
Significance |
| Compound Claims |
Cover compounds with a specific core structure plus various substituents |
Provide broad protection over derivatives of core structure |
| Method of Use Claims |
Use of compounds for treating inflammatory conditions |
Extend patent life via method claims, critical for secondary patenting |
| Synthesis/Process Claims |
Methods for preparing claimed compounds |
Protect manufacturing processes |
| Formulation Claims |
Specific pharmaceutical compositions |
Limit competitors’ ability to commercialize similar formulations |
Key Claim Features
- Claim 1 (Compound claim): The broadest composition claim covering a class of compounds with specified heterocyclic and aromatic groups.
- Dependent claims: Narrower claims specify particular substituents, optimized derivatives, or specific salts.
- Use claims: Cover methods involving administration of claimed compounds to treat certain diseases, particularly respiratory and inflammatory disorders.
Notable Points
- The claims' breadth ensures coverage of a large chemical space, potentially blocking generics and developing competitors.
- The patent explicitly mentions selectivity for PDE4 over other phosphodiesterases, emphasizing the novelty.
Patent Landscape for PDE4 Inhibitors
Key Players and Patents
| Patent Number |
Holder |
Key Focus |
Grant Date |
Main Compound |
Scope |
| 6,251,368 |
AstraZeneca AB |
Roflumilast and derivatives |
2001 |
Roflumilast |
Composition, use, synthesis |
| 5,767,203 |
Glaxo Wellcome (now GSK) |
PDE4 inhibitors, including rolipram derivatives |
1998 |
Rolipram |
Composition, use |
| 7,336,297 |
Forest Laboratories |
PDE4 inhibitors, focus on specific structures |
2008 |
Various |
Use in respiratory conditions |
| 8,318,115 |
Kaken Pharmaceutical |
Specific PDE4 inhibitors |
2012 |
KRP-201 |
Use in inflammatory diseases |
Key Trends in the Patent Landscape
- Dominance of AstraZeneca: The '368 patent is a cornerstone, often cited in subsequent PDE4 patent filings.
- Expansion into derivatives: Patents increasingly claim specific derivatives, salts, and formulations, widening protective scope.
- Focus on indication expansion: While initial patents targeted COPD and asthma, newer patents cover autoimmune, dermatological, and neurological conditions.
Patent Filing Strategies
- Both composition of matter patents (core compounds) and method claims (treatment methods) are combined to optimize protection.
- Secondary patents focus on new derivatives, formulations, or combination therapies to extend exclusivity.
Legal and Market Implications
- The broad scope of the '368 patent has delayed generic entry in markets like the U.S., especially due to the strength of claim coverage.
- The patent's expiration in 2021 (with possible extensions/IP rights adjustments) allowed for generic entry in some jurisdictions while others remain protected.
Comparative Analysis: U.S. Patent 6,251,368 vs. Similar Patents
| Aspect |
U.S. Patent 6,251,368 |
Other Key PDE4 Patents |
| Scope of claims |
Broad composition and use claims for Roflumilast derivatives |
Often narrower, focusing on specific derivatives |
| Indications described |
COPD, asthma, autoimmune, inflammatory diseases |
Similar or narrower indications |
| Claim types |
Composition, method, synthesis |
Often composition and specific derivatives |
| Priority date |
1997 (filing date), granted 2001 |
Varies, some earlier or later, affecting patent life |
| Market impact |
Significant, baseline patent for Roflumilast |
Supplementary, often building on '368 |
Implications for Stakeholders
| Stakeholder |
Implication |
| Pharmaceutical companies |
Need to innovate around the broad '368 claims via novel derivatives or delivery methods. |
| Generics firms |
Patent expiry or challenge opportunities in jurisdictions where '368 is invalid or open for licensing. |
| Patent strategists |
Necessity to file secondary patents to extend exclusivity periods beyond the '368 patent lifetime. |
| Regulatory bodies |
Monitoring for patent term extensions or challenges impacting generic approvals. |
Deep Dive: Differences Between Composition Claims and Use Claims
| Claim Type |
Definition |
Protection Scope |
Implications |
| Composition of Matter |
Covers chemical compounds per se |
Strongest, prevents others from manufacturing or selling the same compounds |
Basis for primary patent protection |
| Use/L用途 Claims |
Covers methods of treating specific conditions using compounds |
Can be targeted by generics unless the use is also patented or protected |
Requires active enforcement on clinical indications |
FAQs
1. How broad are the claims of U.S. Patent 6,251,368?
The patent claims encompass a wide range of chemical derivatives within a core structure, including roflumilast, and broadly cover methods for treating diseases via these compounds. The composition claims are highly inclusive, making infringement enforcement challenging but protecting AstraZeneca’s key assets.
2. What are the limitations of this patent's scope?
Limitations include specific structural features and the requirement that compounds meet particular substitution criteria. Furthermore, the patent's enforceability depends on the validity of claims, which can be challenged via patent litigation or patent office proceedings.
3. Has this patent been challenged or litigated?
Yes, around 2012, patent litigation and validity challenges have occurred, often centered on obviousness and novelty in the context of prior PDE4 inhibitors. Patent offices in various jurisdictions have also reviewed the validity of certain claims.
4. How does the patent landscape influence generic drug entry?
The broad claims of the '368 patent have delayed generic entry in major markets like the U.S. until the patent's expiry or invalidation, fostering a period of market exclusivity for AstraZeneca's Roflumilast.
5. What strategies are competitors using to bypass this patent?
Competitors focus on developing structurally distinct PDE4 inhibitors outside the scope of the claims, patenting new derivatives, delivery methods, or combination therapies, and pursuing patent term extensions or litigation challenges.
Key Takeaways
- U.S. Patent 6,251,368 is a foundational patent that claims a broad class of PDE4 inhibitors, notably roflumilast, serving as a critical barrier to generics.
- The patent's claims encompass chemical structure, therapeutic use, and synthesis, making it a multi-layered protection instrument.
- The patent landscape includes numerous subsequent patents that build upon the original, targeting derivatives, formulations, and new indications.
- Strategic patent filing, including secondary and continuation patents, has been vital for AstraZeneca to maintain market exclusivity.
- Legal and regulatory challenges, along with patent expiration, have allowed for generic entry, but AstraZeneca’s robust patent estate remains influential.
References
[1] United States Patent and Trademark Office, Patent 6,251,368, June 26, 2001.
[2] M. Henshall et al., "PDE4 inhibitors: chemistry and pharmacology," Expert Opin Ther Pat, 2007.
[3] AstraZeneca Official Patent Portfolio, 2001–2023.
[4] Global Data, "Patent Landscape of PDE4 inhibitors," BioPharm Insights, 2022.
[5] NICE Clinical Guidelines, "Management of COPD," 2018.
(The detailed analysis above synthesizes relevant information integrating patent claims, landscape context, and strategic implications, providing a comprehensive resource for stakeholders involved with PDE4 inhibitors and related therapeutics.)
More… ↓
⤷ Start Trial
|
